エドガーで原本を確認する
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 20, 2026
BridgeBio Oncology Therapeutics, Inc.
(Exact name of Registrant as Specified in Its Charter)
| Delaware | 001-41955 | 39-3690783 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
256 E. Grand Avenue, Suite 104
South San Francisco, CA 94080
(Address of principal executive offices, including zip code)
(650) 405-4770
(Telephone number, including area code, of agent for service)
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
||
| Common Stock, par value $0.0001 per share | BBOT | The Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02 | Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Appointment Chief Executive Officer and Director
On April 20, 2026, the Board of Directors (the “Board”) of BridgeBio Oncology Therapeutics, Inc. (the “Company”) approved the appointment of Pedro Beltran, Ph.D., as the Company’s President and Chief Executive Officer (“CEO”) (and as the Company’s principal executive officer), effective immediately. Dr. Beltran succeeds Eli Wallace, Ph.D. in these positions.
Additionally, on April 20, 2026, Dr. Wallace resigned from his position as a member of the Board and as a Class III director, and the Board appointed Dr. Beltran as a Class III director to fill the vacancy created by Dr. Wallace’s resignation, effective immediately. It is expected that Dr. Wallace will continue to serve as an advisor to the Company following his term as President and CEO. Dr. Wallace’s resignation was not the result of any disagreement with the policies, procedures or practices of the Company. The Board thanks Dr. Wallace for his years of service to the Company.
Dr. Beltran, age 55, served as Chief Scientific Officer of the Company (including the Company’s predecessor, TheRas, Inc.) since April 2024 until his appointment as President and CEO. Previously, Dr. Beltran served as Chief Scientific Officer of BridgeBio Pharma, Inc. (Nasdaq: BBIO) from July 2023 to April 2024, and as Senior Vice President of Biology from July 2020 to July 2023. From November 2017 to July 2020, Dr. Beltran was Senior Vice President, Head of Biology at UNITY Biotechnology and from 2003 to 2017 held various roles at Amgen, Inc., including Executive Director of Oncology Research. He has led multiple Investigational New Drug application submissions, authored more than 50 peer-reviewed articles, presented at numerous national and international scientific conferences, and holds diverse patents for the treatment of malignant diseases. Dr. Beltran completed postdoctoral work in Molecular and Cellular Pharmacology at the University of Miami, holds a Ph.D. in Cancer Biology from the University of Texas, MD Anderson Cancer Center, and a B.S. in Molecular Biology from Florida Institute of Technology.
Dr. Beltran is employed on an at-will basis pursuant to an employment agreement with the Company. Dr. Beltran is entitled to receive an annual base salary and an annual target bonus equal to a percentage of his annual base salary, subject to review and adjustment by the Board or the Compensation Committee thereof from time to time. Dr. Beltran is also eligible to receive equity awards and participate in the Company’s employee benefit plans, subject to the terms of such plans. In connection with his appointment as CEO, Dr. Beltran will become entitled to receive severance benefits pursuant to the Company’s Executive Severance Plan as a Tier 1 officer. Dr. Beltran continues to be subject to an existing proprietary information and inventions agreement with the Company. In connection with his appointment as a director, Dr. Beltran also entered into an amended and restated indemnification agreement in the form previously approved by the Board for the Company’s directors.
There are no arrangements or understandings between Dr. Beltran and any other person pursuant to which he was selected as a director, President and CEO. Dr. Beltran does not have any family relationships with any of the Company’s directors, executive officers, or other person nominated or chosen by the Company to become a director or executive officer. There are no transactions between Dr. Beltran and the Company that would be required to be reported under Item 404(a) of Regulation S-K.
Appointment of Chief Operating Officer
On April 20, 2026, the Board also appointed Idan Elmelech as Chief Operating Officer of the Company, effective immediately.
Mr. Elmelech, age 33, served as Senior Vice President, Strategy and Business Development, of the Company (including its predecessor, TheRas, Inc.) from May 2024 until his promotion to Chief Operating Officer. Prior to this role, Mr. Elmelech was Director, Strategy and Business Development at BridgeBio Pharma, Inc. (Nasdaq: BBIO) from July 2023 to April 2024, where he led the $200 million equity financing and spinout of TheRas, Inc. From January 2021 to April 2023, Mr. Elmelech served as a consultant in the life science practice of L.E.K. Consulting, a global management consulting firm, and previously, spent time in early-stage biotechnology venture capital. Mr. Elmelech holds an MBA in Finance from Columbia Business School, an MA in Biotechnology from Columbia University and a BA in Economics and Psychology from Bard College.
Mr. Elmelech is employed on an at-will basis pursuant to an employment agreement with the Company. Mr. Elmelech is entitled to receive an annual base salary and an annual target bonus equal to a percentage of his annual base salary, subject to review and adjustment by the Board or the Compensation Committee thereof from time to time. Mr. Elmelech is also eligible to receive equity awards, to participate in the Company’s employee benefit plans, subject to the terms of such plans, and to receive severance benefits pursuant to the Company’s Executive Severance Plan as a Tier 2 officer. Mr. Elmelech continues to be subject to an existing proprietary information and inventions agreement with the Company. In connection with his promotion to Chief Operating Officer, Mr. Elmelech also entered into an officer indemnification agreement in the form previously approved by the Board for the Company’s executive officers.
There were no arrangements or understandings between Mr. Elmelech and any other persons pursuant to which Mr. Elmelech was selected as Chief Operating Officer. There are no family relationships between Mr. Elmelech and any director or executive officer of the Company, and there are no transactions between Mr. Elmelech and the Company that would be required to be reported under Item 404(a) of Regulation S-K.
The foregoing summaries are qualified in their entirety by reference to the full text of (i) the Company’s Executive Severance Plan, which is filed as Exhibit 10.23 to the Company’s Current Report on Form 8-K filed on August 12, 2025; (ii) the Company’s form of director indemnification agreement, which is filed as Exhibit 10.26 to the Company’s Current Report on Form 8-K filed on August 12, 2025; and (iii) the Company’s form of officer indemnification agreement, which is filed as Exhibit 10.27 to the Company’s Current Report on Form 8-K filed on August 12, 2025, all of which are incorporated herein by reference.
Appointment of Executive Chairman
On April 20, 2026, the Board appointed Neil Kumar, Ph.D., as Executive Chairman of the Board, effective immediately. Jake Bauer, the Chairman of the Board, will continue to serve in such capacity.
Principal Financial Officer and Principal Accounting Officer Transitions
On April 21, 2026, Uneek Mehra, the Company’s Chief Financial Officer, departed from his roles as principal financial officer and principal accounting officer of the Company, and his last day with the Company will be April 30, 2026.
Effective April 21, 2026, the Company’s Board of Directors appointed Mr. Elmelech as the Company’s principal financial officer and Marc Cobo, the Company’s Vice President of Finance and Controller, as the Company’s principal accounting officer.
Mr. Elmelech’s biographical information and the terms of his employment with the Company are set forth above and incorporated herein by reference.
Mr. Cobo, age 46, has served as the Company’s Vice President of Finance and Controller since May 2025. From March 2021 to March 2024, Mr. Cobo served as Executive Vice President and Chief Accounting Officer of SFJ Pharmaceuticals, Inc. Prior to that, Mr. Cobo served as Senior Vice President of Finance and Chief Accounting Officer of Tricida, Inc. (formerly Nasdaq: TCDA), from June 2020 to December 2020. Mr. Cobo holds a B.A. in Accounting from the Santa Clara University Leavey School of Business and is a Certified Public Accountant in the State of California.
Mr. Cobo is employed on an at-will basis pursuant to an employment agreement with the Company. Mr. Cobo is entitled to receive an annual base salary and an annual target bonus equal to a percentage of his annual base salary, subject to review and adjustment by the Company from time to time. Mr. Cobo is also eligible to receive equity awards and participate in the Company’s employee benefit plans, subject to the terms of such plans. Mr. Cobo continues to be subject to an existing proprietary information and inventions agreement with the Company. In connection with his appointment as principal accounting officer, Mr. Cobo will enter into an indemnification agreement in the form previously approved by the Board for officers of the Company.
There are no arrangements or understandings between Mr. Elmelech or Mr. Cobo and any other person pursuant to which each was selected as principal financial officer and principal accounting officer, respectively. Neither Mr. Elmelech nor Mr. Cobo has any family relationships with any of the Company’s directors, executive officers, or other person nominated or chosen by the Company to become a director or executive officer. There are no transactions between Mr. Elmelech or Mr. Cobo and the Company that would be required to be reported under Item 404(a) of Regulation S-K
| Item 7.01 | Regulation FD Disclosure. |
On April 22, 2026, the Company issued a press release regarding certain of the foregoing leadership transitions, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 7.01 and Exhibit 991.1 shall not be deemed “filed” for any purpose, including for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| 99.1 | Press Release dated April 22, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| BRIDGEBIO ONCOLOGY THERAPEUTICS, INC. | ||||||
| Date: April 22, 2026 | By: | /s/ Pedro Beltran |
||||
| Name: Pedro Beltran Title: President and Chief Executive Officer |
||||||
Exhibit 99.1
BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman
Pedro J. Beltran, PhD, a seasoned executive who previously served as Chief Scientific Officer of BBOT, will assume the position of Chief Executive Officer, bringing his extensive drug development experience and scientific/business acumen to bear as the company’s top executive
Idan Elmelech, who previously served as Senior Vice President of Strategy & Business Development, will assume the position of Chief Operating Officer overseeing finance & accounting, corporate strategy, operations, and business development
Neil Kumar, PhD, who played an integral role in the founding of BBOT as part of BridgeBio Pharma, Inc., has been appointed as Executive Chairman by the Board of Directors to guide the company as it embarks on its next stage of development
Former CEO, Eli Wallace, PhD, will serve as a Senior Adviser to the company, continuing to leverage his scientific expertise and deep understanding of BBOT’s programs to support the company going forward
SOUTH SAN FRANCISCO, Calif., April 22, 2026 (GLOBE NEWSWIRE) — BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced the appointment of Pedro J. Beltran, PhD, as Chief Executive Officer and Idan Elmelech as Chief Operating Officer effective April 20th, 2026. This transition reflects BBOT entering a new phase of development as the company’s three clinical assets enter expansions and combinations across multiple RAS-driven cancers. The Board of Directors believes that elevating the next generation of BBOT’s leadership will enable the company to execute with strategic precision and purpose in order to improve outcomes for patients with RAS and PI3Kα malignancies.
“As BBOT’s programs enter Phase 1b expansions in multiple indications across the RAS and PI3Kα space, the company has recognized Pedro and Idan’s strategic vision, scientific acumen, and leadership capabilities to guide the company through its next phase of growth. BBOT is rapidly progressing towards pivotal trials to help more patients afflicted with some of the world’s deadliest cancers. This leadership transition is designed to accelerate and focus the development of BBOT’s programs and continue the company’s ethos of putting patients first,” said Neil Kumar, PhD, Executive Chairman of the Board of Directors.
Dr. Kumar added, “The Board of Directors would like to thank Eli Wallace for his service to the company as CEO and looks forward to continuing to work with him in his new role as Senior Adviser.”
Dr. Beltran brings decades of experience in oncology drug development including 20 years with large pharmaceutical companies. Dr. Beltran joined BridgeBio Pharma in 2020 as Senior Vice President of Biology and became Chief Scientific Officer of BBOT in July 2023. Prior to BridgeBio, Dr. Beltran was Senior Vice President, Head of Biology at UNITY Biotechnology and Executive Director, Oncology Research at Amgen, Inc. Dr. Beltran has led multiple IND filings, authored more than 50 peer-reviewed articles, presented at multiple national/international scientific conferences, and holds diverse patents for the treatment of malignant diseases.
“I am energized and excited to step into the role of CEO as BBOT enters this important new chapter in its short trajectory. I am looking forward to continuing to partner with Idan, our Chief Medical Officer, Yong Ben, the board of directors, and the rest of our mission-driven BBOT team to focus our strategic execution in the pursuit of bringing fast and maximal benefit to patients from our novel therapies,” said Dr. Beltran.
Bihua Chen, Founder and Chief Executive Officer of Cormorant Asset Management and a BBOT director, said “We believe that BBOT is heading towards inflection points across its portfolio. This change in leadership reflects our goal to move with urgency to deliver returns for patients and investors alike.”
About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. Any statements in this press release that are not historical facts may be deemed forward-looking statements, which generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends.
We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements, including express or implied statements relating to the clinical and therapeutic potential of BBOT’s product candidates, BBOT’s plans to accelerate and focus the development of its programs, and the management team’s ability to execute on BBOT’s business strategy, are based on various assumptions, whether or not identified in this press release, and are the current expectations of BBOT’s management and are not predictions of actual performance. Many actual events and circumstances are beyond the control of BBOT. These forward-looking statements are subject to a number of risks and uncertainties, including risks related to the timing of expected regulatory and business milestones, including interactions with regulatory authorities, the progress of enrollment in clinical trials and availability of data from ongoing and planned clinical trials, changes in domestic and foreign business, market, financial, political, and legal conditions, and those factors discussed in documents BBOT has filed or will file with the U.S. Securities and Exchange Commission.
In addition, forward-looking statements reflect BBOT’s expectations, plans, or forecasts of future events and views as of the date of this press release and are qualified in their entirety by reference to the cautionary statements herein. BBOT anticipates that subsequent events and developments will cause BBOT’s assessments to change. These forward-looking statements should not be relied upon as any guarantee, assurance, prediction or definitive statement of fact or probability or as representing BBOT’s assessments as of any date subsequent to the date of this press release. Neither BBOT, nor any of its affiliates undertake any obligation to update these forward-looking statements, except as required by law.
BBOT Contacts:
Investor Contact:
Heather Armstrong, Head of Investor Relations
BBOT
Investors@BBOTx.com
Media Contact:
Totyana Simien
Inizio Evoke Comms
Totyana.Simien@inizioevoke.com